AKASA vs Commure (2026)
Two vendors selling the revenue cycle as a single problem, assembled differently. AKASA runs one engine across coding, documentation integrity and the claim work around them, built as software from the start. Commure assembled its position by acquisition, rolling up scribe, coding and claims businesses so that documentation feeds the revenue cycle inside one company, and it offers a staffing spectrum from fully automated notes through specialist review to synchronous human documentation, which no software only vendor can match. For a health system that wants one platform and one contract across the function, both qualify. The difference is what happens where automation fails: Commure has humans on the payroll to fall back on, and AKASA has software. Ask both for the ratio of codes their systems remove to codes they add.
- One engine spans coding, clinical documentation integrity and the claim work around them, which suits a health system standardising the revenue cycle function on a single vendor.
- The commercial track record is longer in generative revenue cycle work specifically, under an earlier name as well as the current one.
- For an enterprise programme, breadth across the function reduces the handoffs where errors and finger pointing accumulate.
- It offers a staffing spectrum no software vendor matches, from AI drafted notes through specialist review to synchronous human documentation feeding the same revenue cycle.
- The scribe feeds autonomous coding and claims automation inside one company rather than through an integration, which is the reason the platform exists.
- Reach across more than fifty record systems in ambulatory and acute settings, with a published trust centre naming concrete controls.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. AKASA and Commure are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | AKASA | Commure |
|---|---|---|
| Primary category | RCM & Prior Auth AI | Ambient Scribes |
| Founded | Not recorded | 2017 |
| Headquarters | South San Francisco, California | Mountain View, California |
| Website | akasa.com | commure.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards AKASA its top capability grade on AI Centrality, Security Certifications and Trust Center and Setting and Specialty Coverage. Set against Commure, AKASA grades higher on several axes, including Model and Technology Transparency, Model Supply Chain Disclosure and Clinical and Operational Evidence. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards Commure its top capability grade on AI Centrality. Set against AKASA, Commure grades higher on FDA and Regulatory Status and Deployment Model and Data Residency. Its thinnest published disclosure sits on Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose AKASA or Commure?
On the axes where the AI Health Index separates them, AKASA grades higher on several axes, including Model and Technology Transparency, Model Supply Chain Disclosure and Clinical and Operational Evidence, and Commure grades higher on FDA and Regulatory Status and Deployment Model and Data Residency. AKASA leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do AKASA and Commure differ most?
The widest separation the AI Health Index records between AKASA and Commure is on Model and Technology Transparency, where AKASA grades B and Commure grades C. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do AKASA and Commure grade the same?
The AI Health Index grades AKASA and Commure the same on several axes, including AI Centrality, Autonomy and Oversight Model and AI Safety and PHI Stewardship. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have AKASA and Commure not disclosed?
At the last review, at least one of AKASA and Commure published thin or absent detail on Model Supply Chain Disclosure. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the RCM & Prior Auth AI page.
Both sell a return measured by the party being paid for it and neither publishes an independent evaluation. The directional question applies to both: a system tuned to prevent denials and one tuned to maximise capture look identical on every metric either reports, so ask each for its ratio of codes removed to codes added. Neither names a foundation model, describes its architecture or publishes an evaluation methodology. Commure's trust centre purpose limitation permits processing customer data to deliver, improve and support its products, which is broad enough to define in contract.